19. Europäische Aids Konferenz
18. - 21. Oktober 2023 - Warschau, Polen
Der europäische HIV-Kongress fand nach 20 Jahren zum zweiten Mal in Warschau statt. Auf der Tagung wurden viele Daten zu den aktuellen Standardtherapie sowie zu neuen Substanzen in der Entwicklung vorgestellt. Wie gewohnt wurden auch die aktualisierten europäischen Leitlinien zu allen Bereichen der HIV-Infektion präsentiert.
https://eacs-conference2023.com/
EACS 2023 Publikationen Gilead Sciences
Gilead-Abstracts-EACS-2023.pptx
Gilead Abstracts HIV - EACS 2023 – Internal Datasets
B/F/TAF
- Sabranski_Poster_BICSTaR-36M_EACS23_29Sep23.pptx
- Esser_Poster_BICSTaRMentalHealth_EACS_Final_14Oct23_upload.pdf
- Esser_Poster_BICSTaRMentalHealth_EACS_Suppl_Final_16Oct23.pdf
- Pozniak_Poster_Rapid-Restart_EACS2023_09Oct2023_Suppl.pptx
- Pozniak_Poster_Rapid-Restart_EACS2023_SubmissionFile_09Oct2023.pptx
- D-Antoni_Poster-Suppl_CAB-Failure_EACS2023_20Sep2023.pptx
- D-Antoni_Poster_CAB-Failure_EACS2023_26Sept.pptx
LENACAPAVIR
- Margot_EACS23_Week-104-LEN-Resistance-analysis-in-CAPELLA_16Oct23_FINAL.pptx
- Castagna-A_EACS-2023_Follow-Up-of-Injection-Site-Reactions-in-Clinical-Stu-atment.pdf
- Dunbar-M_EACS-2023_Insights-and-Experiences-from-the-CAPELLA-Trial_Perspec-th-HIV.pdf
HIV CURE
EACS 2023 Publikationen - ViiV
|
DOLUTEGRAVIR-based regimens |
|
|
3-Year Outcomes for Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-Treated People Living
with HIV-1 (PLHIV) in Germany: Real-world Data From the German URBAN Cohort |
|
|
Systematic Literature Review of Real-world Experience with the 2-Drug Regimen Dolutegravir +
Lamivudine (DTG + 3TC) in People with HIV-1 (PWH) Aged > 50 Years |
|
|
Real-world effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naïve People with
HIV-1 (PWH) and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review |
|
|
No significant difference in incident hypertension observed by gender, race, baseline BMI or other
key subgroups through week 9 6 a m o n g People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or
Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials |
|
|
CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen
Dolutegravir/Lamivudine Fixed Dose Combination (FDC) in treatment-naïve adults and pre-treated adults who are
virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results. |
|
|
CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment |
|
|
SOLAR 12-month European results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF |
|
|
Efficacy, safety, and implementation outcomes of cabotegravir + rilpivirine long-acting by country in
the cabotegravir and rilpivirine implementation study in European locations (CARISEL) |
|
|
Cabotegravir + rilpivirine long-acting efficacy and safety outcomes by sex at birth, age, and race: a
subgroup analysis of the CARISEL study |
|
|
CABOTEGRAVIR Long-acting for prevention |
|
|
Drivers of discontinuation of oral PrEP within Europe: Findings from a real-world survey of PrEP
use |
|
|
Fostemsavir |
|
|
Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With
HIV-1 Through 96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial |
|
|
Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving
Fostemsavir for up to 5 Years in the BRIGHTE Study |
|
|
Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced
Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHTE Study Through Week 240 |
|
|
Above Brand |
|
|
Drivers of satisfaction and quality of life of people living with HIV within Europe: Findings from a
real-world survey of people living with HIV |
|
|
Patients' fears and expectations related to HIV infection and its treatment in Poland. A
Positive Perspective 2 substudy |
|
|
Other disease-related content |
|
|
Efficacy and Safety of the HIV-1 Maturation Inhibitor G S K 3 6 4 0 2 5 4 + 2 N R T I s in
Treatment-Naive Adults: 2 4 - Week Results From the Phase IIb, Randomized, Dose-Range Finding DOMINO Study |
|
|
Efficacy and Safety of the HIV-1 Maturation Inhibitor G S K 3 6 4 0 2 5 4 ( G S K ’ 2 5 4 ) as Part
of a 2 - Drug Regimen ( 2 D R ) in Treatment-Naive Adults: 24-Week Results from the Phase IIb DYNAMIC Study |
|
|
Safety and Tolerability of V H 3 8 1 0 1 0 9 ( N 6 L S ) Among Antiretroviral Therapy–Naive Adults
Living With HIV-1: Results From the Monotherapy Phase of the Phase IIa BANNER Study |
|
|
Utilizing Population Modeling Approaches to Evaluate the Pharmacokinetics and Virological Activity of
VH 3 8 1 0 1 0 9 (N6LS) in the Phase IIa BANNER Study |
|
Kollegen Fragen
